Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease

被引:72
作者
Finehout, EJ [1 ]
Franck, Z [1 ]
Lee, KH [1 ]
机构
[1] Cornell Univ, Sch Chem & Biomol Engn, Ithaca, NY 14853 USA
关键词
D O I
10.1155/2005/806573
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two-dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change (p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform, expression levels in addition to the more commonly measured total protein expression level.
引用
收藏
页码:93 / 101
页数:9
相关论文
共 26 条
[1]  
[Anonymous], NCBInr protein database
[2]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[3]  
Coleman R M., 1989, Fundamental Immunology, P207
[4]   IMMUNOCYTOCHEMICAL LOCALIZATION OF THE TERMINAL COMPLEMENT COMPLEX IN MULTIPLE-SCLEROSIS [J].
COMPSTON, DAS ;
MORGAN, BP ;
CAMPBELL, AK ;
WILKINS, P ;
COLE, G ;
THOMAS, ND ;
JASANI, B .
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 1989, 15 (04) :307-316
[5]   Towards two-dimensional electrophoresis mapping of the cerebrospinal fluid proteome from a single individual [J].
Finehout, EJ ;
Franck, Z ;
Lee, KH .
ELECTROPHORESIS, 2004, 25 (15) :2564-2575
[6]   Comparison of automated in-gel digest methods for femtomole level samples [J].
Finehout, EJ ;
Lee, KH .
ELECTROPHORESIS, 2003, 24 (19-20) :3508-3516
[7]   Complement components of the innate immune system in health and disease in the CNS [J].
Gasque, P ;
Dean, YD ;
McGreal, EP ;
VanBeek, J ;
Morgan, BP .
IMMUNOPHARMACOLOGY, 2000, 49 (1-2) :171-186
[8]   Proteomics: Theoretical and experimental considerations [J].
Hatzimanikatis, V ;
Choe, LH ;
Lee, KH .
BIOTECHNOLOGY PROGRESS, 1999, 15 (03) :312-318
[9]   IMMUNE-COMPLEXES AND THE COMPLEMENT FACTOR-C4 AND FACTOR-C3 IN CEREBROSPINAL-FLUID AND SERUM FROM PATIENTS WITH CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].
JANS, H ;
HELTBERG, A ;
ZEEBERG, I ;
KRISTENSEN, JH ;
FOG, T ;
RAUN, NE .
ACTA NEUROLOGICA SCANDINAVICA, 1984, 69 (01) :34-38
[10]   Cerebrospinal fluid C3 and C4 indexes in immunological disorders of the central nervous system [J].
Jongen, PJH ;
Doesburg, WH ;
Ibrahim-Stappers, JLM ;
Lemmens, WAJG ;
Hommes, OR ;
Lamers, KJB .
ACTA NEUROLOGICA SCANDINAVICA, 2000, 101 (02) :116-121